Shares of Abbott Laboratories surged 10.9% to $99.04 on July 16 after the healthcare giant delivered a second-quarter earnings surprise that Wall Street didn't see coming. Analysts had forecast adjusted EPS of $1.28 , but Abbott posted $1.31 on revenue of $12.59 billion — topping the $12.52 billion revenue target, which itself reflected 12.3% growth from $11.14 billion a year earlier . For a stock that had fallen nearly 30% over the prior 52 weeks, badly lagging the S&P 500 , the move amounts to the first serious signal that Abbott's growth engine is firing again.

  • The Cancer Diagnostics Deal Is Already Earning Its Keep. Abbott completed its all-cash acquisition of Exact Sciences in March, paying $105 per share in a deal valued at roughly $23 billion including debt . Q2 marks the first full quarter with those cancer-screening revenues on the books. The deal was expected to add about $3 billion of incremental sales in 2026 but dilute adjusted EPS by roughly $0.20 . The fact that Abbott still beat estimates and raised guidance suggests the acquired business is being absorbed faster than investors feared — an important reassurance for shareholders who watched shares drop 6% in April when management first cut its EPS forecast to absorb that dilution .

  • Raised Guidance Tells a Confidence Story. Abbott now projects full-year 2026 adjusted EPS of $5.45 to $5.60 , up from the prior range of $5.38–$5.58. The Street's full-year consensus had been $5.48 , meaning the new midpoint of $5.525 sits above that bar. The lift signals management believes the second-half acceleration — driven by nutrition, heart-rhythm devices, and core lab diagnostics — is on track, not just aspirational.

  • Medical Devices Remain the Profit Engine. Abbott's medical devices franchise, including its continuous glucose monitor and cardiovascular devices, represents its highest-margin growth business . Cardiovascular products were expected to be the biggest contributor to the segment's top line in Q2 , and an earnings beat at this scale implies those businesses delivered. With 28 analysts carrying an average "Buy" rating and a 12-month price target of $116.40 , the stock at $99 still trades at a meaningful discount to the consensus view.

  • The Valuation Question Isn't Settled. Even after today's pop, Abbott sits roughly 24% below analyst targets. Third-quarter EPS guidance of $1.38–$1.46 will need to confirm this isn't a one-quarter wonder. Investors should watch whether cancer-screening revenues accelerate and whether nutrition — Abbott's weakest segment — stops dragging on growth.